TMC-310911
TMC-310911 (also known as ASC-09) is a novel investigational protease
inhibitor (PI) that has been investigated for use in HIV-1 infections
and is structurally similar to the darunavir. TMC-310911 has
demonstrated potential activity against a number of HIV-1 strains,
including multi-PI-resistant strains, and may be less likely to produce
resistance, making it a potentially suitable therapy for patients who
are both native to care and experienced with PI. The Hangzhou-based
Ascletis Pharma, applied to the Chinese authorities in January to study
Ritonavir and TMC-310911 (two HIV protease inhibitor) in clinical trials
for treatment of COVID-19. TMC-310911 as a possible therapy for COVID-19
caused by SARS-CoV-2 in conjunction with other HIV therapies and
antivirals.TMC-310911 is currently being investigated, in combination
with other HIV therapies and antivirals, as a potential treatment for
2019-nCoV [41][42].